Angiogenesis in psoriasis and psoriatic arthritis

Psoriatic and Reactive Arthritis: A Companion to Rheumatology

Volumn , Issue , 2007, Pages 61-64

  Veale, Douglas J ^a   Fearon, Ursula ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882460850     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03622-1.50013-6     Document Type: Chapter

References (33)

1. Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984, 23:246-250.
2. Jones S, Armas JB, Cohen MG, et al. Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994, 33:834-839.
3. Wright V, Roberts MC, Hill AG Dermatological manifestations in psoriatic arthritis: A follow-up study. Acta Derm Venereol 1979, 59:235-240.
4. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994, 33:133-138.
5. Braverman IY, Yen A. Microcirculation in psoriatic skin. J Invest Dermatol 1974, 2:493-502.
6. Braverman IY, Yen A. Ultrastructure of the capillary loops in the dermal papillae of psoriasis. J Invest Dermatol 1977, 68:53-60.
7. Zaric DW, Worm AM, Stahl D, Clemmensen OJ Capillary microscopy of the nailfold in psoriatic and rheumatoid arthritis. Scand J Rheumatol 1981, 10:249-252.
8. Bhushan MM, Moore T, Herrick AL, Griffiths CE Nailfold video capillaroscopy in psoriasis. Br J Dermatol 2000, 142:1171-1176.
9. Hull SG, Goodfield M, Wood EJ, Cunliffe WJ Active and inactive edges of psoriatic plaques: Identification by tracing and investigation by laser-Doppler flowmetry and immunocytochemical techniques. J Invest Dermatol 1989, 92:782-785.
10. Veale DJ, Yanni G, Rogers S, et al. Reduced synovial membrane ELAM-1 expression, macrophage numbers and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993, 36:893-900.
11. Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25:1544-1552.
12. Creamer DJ, Jaggar R, Allen M, et al. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997, 137:851-855.
13. Fraser A, Fearon U, Billinghurst RC, et al. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: Relationship to mediators of systemic and local inflammation. Arthritis Rheum 2003, 48:3085-3095.
14. Fearon U, Reece R, Smith J, et al. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann NY Acad Sci 1999, 878:619-621.
15. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003, 30:260-268.
16. Markham T, Mullan R, Golden-Mason K, et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 2006, 54:1003-1012.
17. DeBusk LM, Chen Y, Nishishita T, et al. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003, 48:2461-2471.
18. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
19. Reece RC, Canete JD, Parsons WJ, et al. Distinct vascular patterns in the synovitis of psoriatic, reactive and rheumatoid arthritis. Arthritis Rheum 1999, 42:1481-1485.
20. Fraser A, Fearon U, Reece R, et al. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001, 44:2024-2028.
21. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-165.
22. Kim HJ, Kim TY Regulation of vascular endothelial growth factor expression by insulin-like growth factor-II in human keratinocytes, differential involvement of mitogen-activated protein kinases and feedback inhibition of protein kinase C. Br J Dermatol 2005, 152:418-425.
23. Morel JCM, Park CC, Zhu K, et al. Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002, 277:34679-34691.
24. Kuo GH, Wang A, Emanuel S, et al. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 2005, 24:1886-1900.
25. Voskas D, Jones N, Van Slyke P, et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. Am J Pathol 2005, 166:843-855.
26. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005, 64:859-864.
27. Karim Z, Wakefield RJ, Quinn M, et al. Validation and reproducibility of ultrasonography in the detection of synovitis in the knee: A comparison with arthroscopy and clinical examination. Arthritis Rheum 2004, 50:387-394.
28. Strieth S, Echhorn ME, Sutter A, et al. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 2006, 119:423-431.
29. Hoff PM, Wolff RA, Bogaard K, et al. A phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol 2006, 36:100-103.
30. Beerepoot LV, Witteveen FO, Groeneweger G, et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: A pharmacokinetic and long-term safety study. Clin Cancer Res 2003, 9:4025-4033.
31. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003, 21:223-231.
32. Goedkoop AY, Kraan MC, Picavet Dl, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy. Arthritis Res Ther 2004, 6:R326-R334.
33. Bongartz T, Coras B, Vogt T, et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: An open-label pilot study. Rheumatology (Oxford) 2005, 44:126-129.